Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHRENILIN vs BUTABARBITAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.
Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.
Tension headache
Sedative,Hypnotic for short-term treatment of insomnia,Preoperative sedation
For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.
Butalbital: terminal half-life ~35 hours (range 20-50 h); acetaminophen: ~2-3 hours (prolonged in hepatic impairment); caffeine: ~3-6 hours.
Terminal elimination half-life is 30-50 hours in adults, which may be prolonged in elderly or patients with hepatic impairment, leading to accumulation with repeated dosing.
Butalbital is extensively metabolized by hepatic CYP450 enzymes (especially CYP2C9) and excreted in urine. Acetaminophen is primarily conjugated in the liver via glucuronidation and sulfation, with minor CYP2E1-mediated metabolism to a toxic metabolite (NAPQI). Caffeine is metabolized predominantly by CYP1A2.
Hepatic metabolism via cytochrome P450 enzymes (primarily CYP2C9 and CYP3A4); undergoes hydroxylation and glucuronidation; active metabolites include hydroxybutabarbital.
PHRENILIN (butalbital/acetaminophen/caffeine): Renal excretion of metabolites; butalbital ~60-70% unchanged in urine, acetaminophen ~2-4% unchanged with majority as glucuronide and sulfate conjugates, caffeine metabolites primarily renal.
Primarily renal, with approximately 60-80% of the dose eliminated as metabolites (mostly hydroxylated and conjugated) and less than 5% as unchanged drug. Minor biliary/fecal excretion occurs (<10%).
Butalbital: ~45% bound to plasma proteins; acetaminophen: 10-25% bound; caffeine: ~35% bound.
Approximately 20-25% bound to plasma proteins, predominantly albumin.
Butalbital: Vd ~0.8 L/kg; acetaminophen: Vd ~0.9 L/kg; caffeine: Vd ~0.6 L/kg. Overall Vd for combination not established; butalbital widely distributed.
Approximately 1.0 L/kg, indicating distribution throughout total body water and extensive tissue binding.
Oral: butalbital ~90% (complete absorption); acetaminophen ~85-90%; caffeine ~100%.
Oral bioavailability is nearly 100% (50-70% reported in some texts, but butabarbital is completely absorbed; first-pass metabolism is minimal).
GFR 30-50 m L/min: Use with caution, maximum 4 capsules per day. GFR <30 m L/min: Avoid use due to accumulation of acetaminophen metabolites and butalbital. Not recommended in dialysis.
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50%.
Child-Pugh A: Use with caution, maximum 4 capsules per day. Child-Pugh B or C: Contraindicated due to impaired metabolism of butalbital and hepatotoxicity risk from acetaminophen.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Not recommended in children under 12 years of age due to butalbital and caffeine content. For adolescents 12-17 years: 1 capsule orally every 4 hours as needed, not exceeding 3 capsules per day.
Children 2-6 years: 25-50 mg orally 3-4 times daily; children 6-12 years: 50-100 mg orally 3-4 times daily; maximum 200 mg/day.
Initiate at 1 capsule orally every 4 hours as needed, not exceeding 4 capsules per day. Monitor for sedation, cognitive impairment, and falls. Avoid in patients with severe hepatic or renal impairment.
Initiate at 25-50 mg orally 3 times daily; increase cautiously to avoid excessive sedation and falls, maximum 200 mg/day.
Barbiturates (butalbital) are habit-forming and may produce drug dependence. Withdrawal symptoms (e.g., anxiety, insomnia, seizures) can occur if abruptly discontinued. Use with caution in patients with a history of substance abuse.
Butabarbital has no FDA boxed warning.
Hepatotoxicity (acetaminophen) with overdose or chronic use; risk of dependence and withdrawal with butalbital; potential for caffeine-related effects (insomnia, palpitations); caution in patients with liver disease, renal impairment, or history of substance abuse.
Risk of dependence, tolerance, and withdrawal symptoms upon discontinuation; respiratory depression, especially with high doses or in patients with respiratory compromise; CNS depression may impair ability to drive or operate machinery; concomitant use with other CNS depressants (e.g., alcohol, opioids) increases risk of profound sedation and respiratory depression; geriatric patients may be more sensitive to effects; use with caution in patients with hepatic or renal impairment.
Hypersensitivity to any component; porphyria (butalbital); severe hepatic impairment (acetaminophen); concurrent use of MAOIs or other CNS depressants may potentiate effects.
Hypersensitivity to barbiturates; porphyria (can exacerbate); severe respiratory insufficiency; history of addiction to sedative-hypnotics; acute or chronic pain (may cause paradoxical excitement); pregnancy (especially third trimester) and lactation.
Avoid or limit caffeine-containing foods and beverages (coffee, tea, cola, chocolate) due to additive caffeine content. Alcohol should be strictly avoided due to enhanced CNS depression and hepatotoxicity risk. Grapefruit juice may affect caffeine metabolism; monitor for increased caffeine effects.
Grapefruit juice may decrease metabolism of butabarbital; avoid concurrent consumption. Alcohol increases CNS depression and should be avoided. No specific food restrictions otherwise.
Butalbital: First trimester: Risk of major malformations (OR 1.4-2.0) including oral clefts; increased risk with prolonged use. Second and third trimesters: Avoid chronic use due to risk of neonatal withdrawal syndrome and hemorrhagic disease of newborn due to vitamin K deficiency. Acetaminophen: Considered low risk; no consistent evidence of teratogenicity. Caffeine: No increased risk of major malformations at moderate intake (<200 mg/day); high doses may be associated with growth restriction.
First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fetal dependence and withdrawal syndrome; neonatal respiratory depression if used near term; increased risk of neurobehavioral effects. Barbiturates cross the placenta rapidly.
Butalbital: Excreted into breast milk; M/P ratio unknown. Monitor infant for sedation, poor feeding, or withdrawal symptoms. Acetaminophen: Excreted in low amounts; M/P ratio approximately 1.0; considered compatible. Caffeine: Excreted in milk; M/P ratio 0.5-0.8; moderate intake likely safe; excessive use may cause irritability in infant.
Butabarbital is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.4–0.6. With therapeutic doses, infant serum levels are usually low; however, chronic high maternal doses may cause sedation or withdrawal in the nursing infant. Caution is recommended; alternate agents may be preferred if infant sedation occurs.
No specific dose adjustments for butalbital or acetaminophen based on pregnancy pharmacokinetics. However, avoid prolonged use or high doses. For caffeine, limit to <200 mg/day. Use lowest effective dose for shortest duration. Monitor for signs of butalbital accumulation in pregnancy due to increased volume of distribution; no formal recommendation for dose reduction.
Pregnancy can alter butabarbital pharmacokinetics due to increased hepatic metabolism and volume of distribution. Serum concentrations may decrease; therapeutic drug monitoring is recommended if used chronically. Dose adjustments may be necessary to maintain efficacy, but due to risks, use is generally avoided. If used, start with lowest effective dose and monitor for clinical response and toxicity.
Phrenilin is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; use with caution in patients with history of substance abuse or depression. Acetaminophen hepatotoxicity risk increases with doses >4g/day or in alcohol use disorder. Caffeine may exacerbate anxiety, insomnia, or tachyarrhythmias. Monitor for sedation and respiratory depression when used with other CNS depressants. Avoid abrupt discontinuation to prevent withdrawal symptoms.
Butabarbital is a short-acting barbiturate with rapid onset. It is primarily used for sedation and insomnia but has high abuse potential. Avoid use in patients with porphyria, severe hepatic impairment, or respiratory insufficiency. Abrupt discontinuation after prolonged use may precipitate withdrawal including seizures. Barbiturates induce CYP3A4 and other hepatic enzymes, reducing efficacy of oral contraceptives, warfarin, and corticosteroids. Use with caution in elderly due to increased risk of falls and cognitive impairment.
Take only as prescribed; do not exceed recommended dose to avoid liver damage or addiction.,Avoid alcohol while taking this medication due to increased risk of liver toxicity and sedation.,Do not drive or operate heavy machinery until you know how this medication affects you.,If you have a history of substance abuse, inform your doctor before taking this medication.,Common side effects include drowsiness, dizziness, and nausea. Report severe allergic reactions or signs of liver damage (yellowing skin/eyes, dark urine, abdominal pain).,Do not stop taking suddenly without consulting your doctor, as withdrawal symptoms may occur.,Keep out of reach of children; acetaminophen overdose can be fatal.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop taking suddenly as withdrawal reactions such as anxiety, tremors, or seizures can occur.,May cause drowsiness or dizziness; do not drive or operate machinery until you know how this medicine affects you.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) as they increase risk of severe sedation and respiratory depression.,Use effective contraception while taking this medication as it may reduce hormonal contraceptive effectiveness.,Store in a secure place away from children and others, as it can cause dependence and is habit-forming.
No interactions on record
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHRENILIN vs BUTABARBITAL, answered by our medical review team.
PHRENILIN is a Barbiturate/Analgesic Combination that works by PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.. BUTABARBITAL is a Barbiturate that works by Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHRENILIN and BUTABARBITAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHRENILIN is: For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.. The standard adult dose of BUTABARBITAL is: 50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHRENILIN and BUTABARBITAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHRENILIN is classified as Category C. Butalbital: First trimester: Risk of major malformations (OR 1.4-2.0) including oral clefts; increased risk with prolonged use. Second and third trimesters: Avoid chronic use due t. BUTABARBITAL is classified as Category C. First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.